



RealRate











PHARMACEUTICAL 2022





Karuna Therapeutics Inc. Rank 68 of 466

The relative strengths and weaknesses of Karuna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karuna Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Karuna Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 260%, being 182% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	517,334
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,213
Liabilities, Non-Current	5,432
Other Assets	7,245
Other Compr. Net Income	-536
Other Expenses	6.0
Other Liabilities	0
Other Net Income	54
Other Revenues	36,964
Property and Equipment	3,092
Research and Development	128,200
Selling, General and Administrative Expense	52,617

Output Variable	Value in 1000 USD
Assets	527,671
Liabilities	25,645
Expenses	180,823
Revenues	36,964
Stockholders Equity	502,026
Net Income	-143,805
Comprehensive Net Income	-144,073
Economic Capital Ratio	260%

